Jump to main content
Jump to site search

Issue 8, 2017
Previous Article Next Article

Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy

Author affiliations

Abstract

Combination cancer therapy possesses considerable appeal due to its many merits such as enhancing efficacy by synergistic effects and overcoming drug resistance as compared to monotherapy. Nanomedicine-mediated co-delivery of multiple anticancer agents is more effective than conventional cocktail-based physical mixture of free drugs. A strategy is required to differentiate their unique targets for maximizing the synergistic effects based on individual sites of action of different drugs. This review summarizes the recent progresses in nanomedicine-based combination cancer therapies using site-specific co-delivery strategies, which have been classified by different target sites at the anatomical scales such as tissue, cellular and subcellular levels. In particular, the design of materials and formulations functionalized with tumor-associated signal-responsive elements has been highlighted. The potential and perspective of future developments have also been discussed.

Graphical abstract: Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy

Back to tab navigation

Publication details

The article was received on 03 Apr 2017, accepted on 14 Jun 2017 and first published on 30 Jun 2017


Article type: Review Article
DOI: 10.1039/C7BM00297A
Citation: Biomater. Sci., 2017,5, 1367-1381
  •   Request permissions

    Recent progress in nanomedicine-based combination cancer therapy using a site-specific co-delivery strategy

    S. Shen, M. Liu, T. Li, S. Lin and R. Mo, Biomater. Sci., 2017, 5, 1367
    DOI: 10.1039/C7BM00297A

Search articles by author

Spotlight

Advertisements